Known targets — ChEMBL curated mechanism
AGTR1DHFRGABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTNR3C2PBP2XPTGS1PTGS2VKORC1blablaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAftsImrcAmrcBmrdApbp1apbp1bpbp2apbp2bpbp3polthyA
The experimentally established mechanism targets of Potassium Ion. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 1/20 | 0.38 |
| ▸ | HTR2C | P28335 | 1/20 | 0.38 |
| ▸ | CYP11B1 | P15538 | 7/20 | 0.38 |
| ▸ | CYP11B2 | P19099 | 7/20 | 0.38 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.35 |
| ▸ | CDK9 | P50750 | 3/20 | 0.34 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.34 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.34 |
| ▸ | MGLL | Q99685 | 1/20 | 0.33 |
| ▸ | DRD3 | P35462 | 2/20 | 0.32 |
| ▸ | DRD4 | P21917 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16814051 | 0.81 | NTRK1 (0.40) | HTR2AHTR2CCYP11B1CYP11B2NTRK1 | |
| SCHEMBL20207558 | 0.77 | NTRK1 (0.40) | HTR2AHTR2CCYP11B1CYP11B2NTRK1 | |
| SCHEMBL25172258 | 0.76 | HTR2A (0.43) | HTR2AHTR2CCYP11B1CYP11B2CDK9 | |
| SCHEMBL4820236 | 0.73 | LMNA (0.48) | DRD3DRD4KDM4ENPC1ALDH1A1 | |
| SCHEMBL24577981 | 0.72 | CYP11B1 (0.38) | HTR2AHTR2CCYP11B1CYP11B2NTRK1 | |
| SCHEMBL20223637 | 0.72 | HTR2A (0.43) | HTR2AHTR2CNTRK1CDK9SSTR4 | |
| SCHEMBL23056002 | 0.72 | HTR2A (0.36) | HTR2AHTR2CCYP11B1CYP11B2NTRK1 | |
| SCHEMBL24567548 | 0.69 | TSHR (0.50) | NTRK1DRD3KDM4EALDH1A1HPGD | |
| Iodide SCHEMBL7949135 | 0.69 | HTR2A (0.39) | HTR2AHTR2CNTRK1CDK9SSTR4 | |
| SCHEMBL15528465 | 0.68 | LRRK2 (0.40) | CYP11B1CYP11B2CDK9SSTR4NLRP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080009634-A1 | Process for synthesizing beta-lactamase inhibitor intermediates | WYETH HOLDINGS CORPORATION (US) | 2008-01-10 | — | — | US | disclosed |
| US-7276611-B2 | Process for synthesizing beta-lactamase inhibitor intermediates | WYETH HOLDINGS CORPORATION (US) | 2007-10-02 | — | — | US | disclosed |
| EP-1626975-A2 | PROCESS FOR SYNTHESIZING ß-LACTAMASE INHIBITOR IN INTERMEDIATES | Wyeth Holdings Corporation (US) | 2006-02-22 | — | — | EP | disclosed |
| WO-2004104006-A2 | PROCESS FOR SYNTHESIZING β-LACTAMASE INHIBITOR IN INTERMEDIATES | WYETH HOLDINGS CORPORATION (US) | 2004-12-02 | — | — | WO | disclosed |
| US-20040242874-A1 | Process for synthesizing beta-lactamase inhibitor intermediates | WYETH HOLDINGS CORPORATION | 2004-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080009634-A1 | Process for synthesizing beta-lactamase inhibitor intermediates | COASY, DCXR, MGAM | HTR2A 3395/4885HTR2C 3603/4885CYP11B1 1627/4885 |
| US-20040242874-A1 | Process for synthesizing beta-lactamase inhibitor intermediates | COASY, DCXR, MGAM | HTR2A 3362/4885HTR2C 3537/4885CYP11B1 1650/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.